Corey S. Cutler, MD, MPH, FRCPC

Sharing closing thoughts on acute and chronic GVHD management, expert panelists first consider the value of multidisciplinary care.

Shifting their focus to acute graft versus host disease, panelists reflect on evolving treatment strategies and novel therapeutics.

Expert panelists share their perspectives on ongoing treatment evolutions in the setting of chronic graft versus host disease.

Following their review of available treatment for steroid refractory chronic GVHD, experts consider how they would optimally select and sequence therapy.

Comprehensive discussion on each of the 3 standard-of-care treatment options for patients with steroid refractory chronic GVHD.

An overview of the frontline treatment armamentarium for patients diagnosed with chronic graft versus host disease.

Shifting their focus to chronic graft versus host disease, panelists emphasize the importance of early identification and diagnosis.

Expert panelists review the role of the microbiome in the context of hematopoietic stem cell transplantation and steroid-refractory acute GVHD.

Key opinion leaders highlight the value of clinical trials and share their perspective on enrolling patients in the setting of acute GVHD.

Comprehensive discussion on the treatment options available for patients diagnosed with steroid-refractory acute GVHD.

A brief review of the evolving utilization of biomarker testing in acute graft versus host disease, particularly for prognostic evaluation.

Focusing on acute graft versus host disease, panelists consider tools and methods that help to overcome challenges in making a differential diagnosis.

Expert perspectives on how best to educate patients and caregivers on graft versus host disease symptoms and quality of life.

Shared insight on standard-of-care prophylactic methods employed in the management of patients with graft versus host disease.

Expert panelists spearhead a discussion on the pathophysiology driving both acute and chronic graft versus host disease.

Expert perspectives on novel transplantation strategies to prevent or improve outcomes in graft-versus-host disease.

Brief insight on the FLIGHT and AGAVE-201 trials in chronic GVHD, which analyzed itacitinib, a JAK inhibitor, and axatilimab, a CSF1R inhibitor, respectively.

Considerations for novel treatment approaches with approved agents in combination or the frontline setting of chronic graft-vs-host disease.

Shared insight on how best to select ibrutinib, belumosudil, or ruxolitinib for patients with steroid-refractory chronic graft-vs-host disease.

Closing out his summation of ruxolitinib in chronic GVHD, Yi-Bin Chen, MD, considers how real-world use compares with the REACH3 trial results.